S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:ANAB

AnaptysBio (ANAB) Stock Forecast, Price & News

$18.00
-0.54 (-2.91%)
(As of 09/20/2023 ET)
Compare
Today's Range
$17.95
$18.71
50-Day Range
$16.74
$20.56
52-Week Range
$16.66
$32.44
Volume
156,027 shs
Average Volume
246,213 shs
Market Capitalization
$477.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.75

AnaptysBio MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
93.1% Upside
$34.75 Price Target
Short Interest
Bearish
19.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.44mentions of AnaptysBio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$116,257 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.61) to ($6.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

862nd out of 961 stocks

Pharmaceutical Preparations Industry

418th out of 453 stocks


ANAB stock logo

About AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB Price History

ANAB Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
AnaptysBio (NASDAQ: ANAB)
JP Morgan Upgrades AnaptysBio (ANAB)
When Will AnaptysBio, Inc. (NASDAQ:ANAB) Breakeven?
AnaptysBio: Upside Could Be Lying Ahead Very Nicely
See More Headlines
Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Company Calendar

Last Earnings
8/07/2023
Today
9/20/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANAB
Fax
N/A
Employees
96
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$34.75
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+93.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-128,720,000.00
Net Margins
-1,113.38%
Pretax Margin
-1,113.19%

Debt

Sales & Book Value

Annual Sales
$10.29 million
Book Value
$9.22 per share

Miscellaneous

Free Float
17,122,000
Market Cap
$477.90 million
Optionable
Optionable
Beta
-0.16

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Daniel R. Faga (Age 43)
    Pres, CEO & Director
    Comp: $867.12k
  • Mr. Eric J. LoumeauMr. Eric J. Loumeau (Age 60)
    Chief Legal Officer
    Comp: $685.59k
  • Mr. Hamza Suria M.B.A. (Age 47)
    M.Sc., Advisory
    Comp: $3.06M
  • Dr. Paul F. Lizzul FAAD (Age 48)
    M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer
    Comp: $656.36k
  • Mr. Dennis M. Mulroy (Age 68)
    Chief Financial Officer
  • Mr. Benjamin Stone
    Sr. VP of Corp. Devel.
  • Ms. Beth Mueller
    Sr. VP of HR
  • Dr. Martin Dahl Ph.D.
    Sr. VP of Research













ANAB Stock - Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View ANAB analyst ratings
or view top-rated stocks.

What is AnaptysBio's stock price forecast for 2023?

5 analysts have issued 12 month price targets for AnaptysBio's shares. Their ANAB share price forecasts range from $26.00 to $45.00. On average, they predict the company's stock price to reach $34.75 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price.
View analysts price targets for ANAB
or view top-rated stocks among Wall Street analysts.

How have ANAB shares performed in 2023?

AnaptysBio's stock was trading at $30.99 on January 1st, 2023. Since then, ANAB shares have decreased by 41.9% and is now trading at $18.00.
View the best growth stocks for 2023 here
.

When is AnaptysBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ANAB earnings forecast
.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($1.50) EPS for the quarter, beating analysts' consensus estimates of ($1.65) by $0.15. The biotechnology company earned $3.46 million during the quarter, compared to analysts' expectations of $5.50 million. AnaptysBio had a negative trailing twelve-month return on equity of 65.52% and a negative net margin of 1,113.38%.

What ETF holds AnaptysBio's stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 5,859 shares of ANAB stock, representing 1.01% of its portfolio.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.87%), Point72 Asset Management L.P. (5.50%), State Street Corp (4.57%), Braidwell LP (4.35%), Woodline Partners LP (3.90%) and Dimensional Fund Advisors LP (3.42%). Insiders that own company stock include Ecor1 Capital, Llc, Eric J Loumeau, Hamza Suria and Paul F Lizzul.
View institutional ownership trends
.

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $18.00.

How much money does AnaptysBio make?

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $477.90 million and generates $10.29 million in revenue each year. The biotechnology company earns $-128,720,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.

This page (NASDAQ:ANAB) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -